Skip to main content

Table 1 Patient demographics for the time cohort

From: The effect of preventative cardiovascular therapies on coronary artery disease in people with and without type 2 diabetes: a propensity-matched score study

Characteristics

No diabetes (n = 1421)

T2DM (n = 1421)

Standardised difference (%)

P value

Age, median (IQR)

67.6 (58.8, 75.5)

67.0 (59.1, 73.7)

1.9

0.22

Gender (Male)

921 (64.8%)

875 (61.6%)

6.7

0.07

Country of birth

Non-Australian

435 (30.6%)

432 (30.4%)

0.5

0.80

Australian

933 (65.7%)

929 (65.4%)

0.6

 

Unknown

53 (3.7%)

60 (4.2%)

2.5

 

Language spoken

English

1253 (88.2%)

1253 (88.2%)

0.0

0.93

Not English

121 (8.5%)

124 (8.7%)

0.8

 

Unknown

47 (3.3%)

44 (3.1%)

1.2

 

SEIFA Index, median (IQR)

6.0 (4.0, 7.0)

6.0 (4.0, 7.0)

0.7

0.57

Stage of CKD

No known CKD

1343 (94.5%)

1333 (93.8%)

3.0

0.96

CKD stage 2

6 (0.4%)

5 (0.4%)

1.1

 

CKD stage 3

41 (2.9%)

45 (3.2%)

1.6

 

CKD stage 4

15 (1.1%)

18 (1.3%)

2.0

 

CKD stage 5

12 (0.8%)

15 (1.1%)

2.2

 

CKD stage unknown

4 (0.3%)

5 (0.4%)

1.3

 

Indication for angiogram

Chest pain

317 (22.3%)

315 (22.2%)

0.2

1.00

History of acute coronary event

120 (8.4%)

121 (8.5%)

  

Breathlessness

115 (8.1%)

119 (8.4%)

  

Positive non-invasive test

504 (35.5%)

506 (35.6%)

  

Other

365 (25.7%)

360 (25.3%)

  

Year of angiogram

2013

141 (9.9%)

147 (10.3%)

2.0

0.95

2014

210 (14.8%)

207 (14.6%)

  

2015

208 (14.6%)

206 (14.5%)

  

2016

209 (14.7%)

220 (15.5%)

  

2017

229 (16.1%)

242 (17.0%)

  

2018

226 (15.9%)

209 (14.7%)

  

2019

198 (13.9%)

190 (13.4%)

  

Valvular disease

140 (9.9%)

145 (10.2%)

1.2

0.75

Peripheral vascular disorders

30 (2.1%)

34 (2.4%)

1.9

0.61

Congestive heart failure

133 (9.4%)

135 (9.5%)

0.5

0.90

Cardiac arrhythmia

103 (7.2%)

107 (7.5%)

1.1

0.77

Hypertension

201 (14.1%)

190 (13.4%)

2.2

0.55

  1. Other Elixhauser comorbidities matched included; pulmonary circulation disorders, other neurological disorders, chronic obstructive pulmonary disease, renal failure, liver disease, metastatic cancer, solid tumour without metastasis, rheumatoid arthritis/collagen vascular disease, coagulopathy, obesity, weight loss, fluid and electrolyte disorders, blood loss anaemia, deficiency anaemia, alcohol abuse and depression